Rapid Therapeutic Science Laboratories Inc logo

RTSL - Rapid Therapeutic Science Laboratories Inc News Story

$0.71 -0.0  -2.5%

Last Trade - 27/11/20

Small Cap
Market Cap £97.6m
Enterprise Value £97.9m
Revenue £105k
Position in Universe 4224th / 6429

Rapid Therapeutic Science Laboratories, Inc. Highlighted in Research Report Released by Emerald Equity Research, LLC

Rapid Therapeutic Science Laboratories, Inc. Highlighted in Research Report Released by Emerald Equity Research, LLC

DALLAS, June 22, 2020 (GLOBE NEWSWIRE) -- Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) an SEC fully-reporting, growth-oriented company focused on manufacturing and marketing CBD aerosol delivery systems based on pressurized Metered Dose Inhaler (MDI) technology, announced today that Emerald Equity Research, LLC has initiated research coverage on the Company.

To view and download the report (at no cost) CLICK HERE.

Rapid Therapeutic Science Laboratories, Inc. Chairman and CEO, Donal R. Schmidt, Jr. stated, “We are extremely pleased to announce the availability of an in-depth analysis of the Company’s market focus, business process and investment opportunity by a well-respected, equity research analyst such as Mr. Connell.”

Sean Berrier, Sr. VP and Co-founder commented about the usage of RTSL’s products, stating that “MDIs deliver Active Pharmaceutical Ingredients (API’s) into the blood stream within seconds of inhalation. RTSL’s MDIs are a safe and convenient replacement for vape pens, tanks, and mods, and deliver a 98% bioavailable dose of CBD.”

Mr. Berrier continued, “We manufacture white label products as well as our own metered dose inhalers under the Rxoid™ name, using proprietary blends of pure cannabinoids such as CBD and/or CBG. Unlike some companies in the MDI industry, we do not use “full spectrum” oil or any other excipient not approved for human inhalation. RTSL’s MDI products are made using filling equipment, consumables (cans, valves, and actuators) and propellant listed in the FDA Drug Master Files (DMF) and contain no tetrahydrocannabinol (THC). RTSL is certified by CMDICB for product safety and its MDIs are covered by product liability insurance.”

"The Emerald Equity Research report covers the unique aspects of RTSL’s business model, its science and technology, and the multi-year P&L financial forecast model gives investors a more detailed understanding of the true revenue and earnings power of our Company," said Mr. Schmidt.

The research report is available HERE.

About Emerald Equity Research, LLC

Emerald Equity Research, LLC is one of a new breed of issuer-sponsored research boutiques, providing unbiased equity research coverage to smaller issuers that cannot attract research coverage from traditional brokerage firm’s research departments. Our mission is to help both investors and public issuers by improving the availability of issuer information and by providing sound, unbiased analysis of our issuer clients’ businesses, industries, and current market valuation.

The policies of Emerald Equity Research, LLC require that all personnel strictly adhere to the CFA Institute’s Code of Ethics and Standards of Professional Conduct, and its Best Practice Guidelines Governing Analyst / Corporate Issuer Relations. Please see www.cfainstitute.org for more information.

About Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)

RTSL has developed and perfected a new method of formulation and manufacturing to deliver pure CBD, CBG and/or THC and combinations thereof in legal jurisdictions to consumers through an FDA approved medical device known as a pressurized Metered Dose Inhaler (MDI). The Rxoid MDI product line is manufactured in compliance with cGMP on FDA approved equipment. Non-THC Cannabinoids are not yet approved by the FDA but are legal to consume in TX and many other states and export to legal foreign jurisdictions.

A MDI is a replacement for vape pens, as it uses no heat and needs no dangerous ingredients to work. In addition, MDIs are less expensive than any other route of delivery measured by blood serum levels. They are however expensive to formulate and manufacture so that they legally and properly work as an MDI under FTC rules on truth and labeling.

RTSL markets its Rxoid™ MDI products directly to pharmacies and physicians who treat GAD, PTSD and other stress and anxiety disorders.

RTSL’s MDI products also can be purchased by consumers online at www.rxoid.com.

We encourage all customers to do their own research regarding cannabinoids, the use of MDIs and our products. RTSL makes no claims about therapeutic benefits of its products. None of our products are intended to diagnose, treat, cure or prevent any disease. Always consult a physician prior to using any cannabinoid product. If you experience any adverse reaction stop use immediately and seek appropriate medical attention. RTSL’s products are not approved by the FDA or under the Food Drug & Cosmetics Act (FD&C Act).

Visit our corporate website at www.rtslco.com.

Forward-Looking Statements 
This press release may contain forward-looking statements. In particular, when used in the preceding discussion, the words “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of RTSL, its divisions and concepts to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in filings made by RTSL with the Securities and Exchange Commission, including, but not limited to, in the “Risk Factors” sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which we have filed, and file from time to time, with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov. Other unknown or unpredictable factors also could have material adverse effects on RTSL’s future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. RTSL cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Donal (Don) R. Schmidt, Jr.
Chairman and CEO
Phone: 800-497-6059
Fax: 877-676-8527

Source: Rapid Therapeutic Science Laboratories, Inc.

© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.